Evaluation of two commercially available rapid diagnostic tests for Lyme borreliosis
|
|
- Alisha Eaton
- 6 years ago
- Views:
Transcription
1 DOI /s ARTICLE Evaluation of two commercially available rapid diagnostic tests for Lyme borreliosis P. W. Smit & S. Kurkela & M. Kuusi & O. Vapalahti Received: 26 June 2014 /Accepted: 17 July 2014 # Springer-Verlag Berlin Heidelberg 2014 Abstract The diagnosis of Lyme disease is very complicated and a single diagnostic method cannot exclude infection. We assessed the performance of two commercially available Borrelia burgdorferi rapid diagnostic tests (RDT) in comparison to multiple laboratory-based diagnostic assays using specimens with a gradually increasing probability of Borrelia infection. Based on 200 specimens, the analytical sensitivities for IgG and IgM were 18 and 23 % for the Lyme RDT and 24 and 32 % for the Borreliose Complete RDT. The sensitivity for detecting diagnosed Lyme borreliosis cases was low (26 % Lyme RDT and 32 % with the Borreliose Complete RDT respectively), whereas the specificity was good (85 % Lyme RDT and 88 % Borreliose Complete). Based on this evaluation, the performance of RDTs in detecting Lyme borreliosis appeared to be below that of laboratory-based diagnostics. Introduction Borrelia burgdorferi sensu lato includes 18 closely related species, but only three cause Lyme disease (Lyme borreliosis): P. W. Smit European Program for Public Health Microbiology Training, European Centre for Disease Prevention and Control, Stockholm, Sweden P. W. Smit (*): M. Kuusi Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Helsinki, Finland pieterwsmit@gmail.com S. Kurkela: O. Vapalahti Faculty of Medicine, University of Helsinki, Helsinki, Finland S. Kurkela: O. Vapalahti Helsinki University Central Hospital Laboratory, Helsinki, Finland O. Vapalahti Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland B. burgdorferi sensu stricto, B. afzelii and B. garinii [1, 2]. The number of reported Lyme borreliosis cases is steadily increasing in Finland. In 2013, a total of 1,707 cases were recorded in Finland, with the highest incidence in Åland (1,621/100,000) [3]. Diagnosis of Lyme disease is complex and early infections are particularly challenging for physicians as laboratory-based tests cannot be used [4]. For late phase infections, diagnosis often involves a two- or three-tier laboratory test setup combined with assessment of clinical symptoms by a physician [2, 5, 6]. Even though the diagnosis is complex, rapid diagnostic tests (RDTs) are commercially available at pharmacies in Europe, for use by non-clinicians. RDTs require only a drop of blood, can be performed with minimal training, and are suitable for use in a non-laboratory setting. There are no regulations governing the performance of RDTs and published evaluations are not available. Studies evaluating the performance of RDTs for other spirochete bacteria, such as Treponema pallidum, have shown reasonable sensitivity and specificity [7]. Because of the high incidence in Finland and wide concern regarding ticks, the general public may frequently use RDTs for self-diagnosis. This could affect healthcare-seeking behaviour in the case of tick bites. There is a clear need to evaluate the performance of Borrelia burgdorferi RDTs compared with standard laboratory-based diagnostic assays. To reflect the multistep decision-making process of the clinical and laboratory-based diagnoses of Borrelia, the performance of RDTs was assessed using specimens with a gradually increasing probability of Borrelia infection. Materials and methods Study setting and specimens Lyme disease is mandatorily recorded by physicians and microbiological laboratories at the National Infectious Disease
2 Registry in Finland. Lyme borreliosis laboratory diagnostics are centralised to a limited number of laboratories in Finland. The laboratory involved in this project, the Department of Virology and Immunology, Helsinki University Central Hospital Laboratory HUSLAB, receives serum specimens from suspected Lyme borreliosis cases from general practitioners and hospitals throughout Finland. Data on symptoms were occasionally provided by the treating physician when sending the specimens to the laboratory for analysis. Therefore, data on Lyme disease-related symptoms were included in the study where possible. No information on duration of disease at the time of sampling could be obtained. Specimens and reference tests The sampling frame comprised 13,510 serum specimens that were tested with six serological laboratory tests for routine borrelia diagnostics. Two enzyme linked immunosorbent assays (ELISA), the Borrelia afzelii and VlsE IgG (Sekisui Virotech, Rüsselsheim, Germany) and the Borrelia afzelii IgM ELISA kit (Sekisui Virotech), acted as primary tests. As secondary tests, the chemiluminescence immunoassays (CLIA) Liaison Borrelia IgG and the Liaison Borrelia IgM (DiaSorin) were used. In the event of discordance between these two tests or when requested by the treating physician, the Borrelia Europe Plus TpN17 Line IgG Line Immunoblot (Sekisui Virotech) and the Borrelia Europe LINE IgM Line Immunoblot (Sekisui Virotech) were performed. A positive reaction for the IgG immunoblot required distinct reactions against at least two of the antigens included in the assay (OspC, VlsE-mix, p39, DbpA-mix, p58 or p83). A positive reaction for the IgM immunoblot required distinct reactions against at least two of the antigens included in the assay (OspC, VlsE-mix, p39, or DbpA-Mix) or a distinct reaction against OspC alone. In order to assess the analytical sensitivity of the RDTs, antibody concentrations were estimated by categorising the combined CLIA and ELISA test result values into low/ intermediate concentration, , and high concentration, 180 [8]. The linear measurement ranges were 9 40 VE/ml for the Sekisui Virotech test, and AU/ml for the DiaSorin test. Cross reaction with syphilis may occur and we therefore selected syphilis-positive specimens, diagnosed by a reactive CLIA (LIASON, treponema screen, DiaSorin), and TPPA (Serodia, Fujirebio, Japan) with a non-reactive Borrelia IgM and IgG ELISA. The laboratory participates four times per year in EQA programs (Labquality) for both Lyme borreliosis and syphilis. Specimens were collected and routinely tested for Lyme borreliosis between April 2013 and March 2014 and stored at 20 C until used in this study in April The sera had therefore undergone one freeze thaw cycle before this study. The specimens were listed in the laboratory database according to date of specimen. To select specimens with a gradually increasing probability of Borrelia infection, a random starting point within the sampling frame was chosen and specimens were systematically selected until each possible combination of negative, low, or high IgM antibody concentration and negative, low, or high IgG antibody concentration was found (see Table 2). For specimens confirmed with immunoblot, however, a convenience sampling was conducted because of the limited number of specimens available within the sampling frame. According to the Finnish National Guidelines, serodiagnoses of Lyme borreliosis cases are based on high IgG values with reactive ELISA/CLIA test or positive immunoblot [IgM or IgG]). Rapid diagnostic tests The Lyme IgM (VEDA.LAB, Alecon, France; lot: 13042), Lyme IgG (VEDA.LAB, Alecon, France; lot: ), and the Keul-o-test Borreliose Complete IgM and IgG test (Borreliose Complete; BioGenTechnologies, Steinfurt, Germany); lot: ) were performed. The Lyme IgM and Lyme IgG RDTs are sold as separate tests, while the Borreliose Complete RDT combines IgG and IgM detection in one plastic cassette. According to the manufacturer s instructions, the test can be used with 50 μl of whole blood or 25 μl serum. The latter sample type was chosen for this evaluation and a timer was used to ensure that the test was read after 10 to 15 min. All tests were performed according to the manufacturer s instructions. Ethics Ethics approval was obtained from the Hospital District of Helsinki and Uusimaa committee. Data were analysed using Stata12 (StataCorp, College Station, TX, USA). Results Two Borrelia IgM and two Borrelia IgG RDTs were evaluated with a retrospective panel of 200 specimens. To assess the performance of these tests, specimens were divided into a spectrum of gradually increasing probability of infection (Table 1). The overall analytical sensitivity for IgG was 18 % for the Lyme RDTand 24 % for the Borreliose Complete RDT. For IgM, the analytical sensitivity was higher, 23 % for the Lyme RDT and 32 % for the Borreliose Complete RDT (Table 1). Based on the analysis of the 82 negative specimens, the analytical specificity of the RDTs ranged from %, none cross reacted with treponemal antibodies (Table 1).
3 Table 1 Performance of the Lyme and Borreliose Complete IgM and IgM-specific tests. Results (N=200) are given in comparison with reference tests, IgG positivity and with cases diagnosed with Lyme borreliosis Lyme RDTs Borreliose Complete RDT IgG IgM IgG IgM Number % Number % Number % Number % Reference test N=200 Negative (4 syphilis positive) Low antibody levels a High antibody levels a ELISA, CLIA and immunoblot positive b ELISA, CLIA, immunoblot positive b and clinical symptoms IgG N=200 IgG Neg IgGPos Diagnosed cases N=200 Lyme borreliosis-positive cases Lyme borreliosis-negative cases ELISA enzyme-linked immunosorbent assay, CLIA chemiluminescence immunoassays a Antibody levels based on ELISA and CLIA results without immunoblot b Immunoblot positive with high and/or low antibody levels (ELISA and CLIA results) Based on the 91 specimens that would be diagnosed and reported as Lyme borreliosis-positive cases (high IgG with ELISA and CLIA, or positive immunoblot [IgM or IgG]), 24 (26, 95 % confidence interval [CI]: %) were positive according to Lyme RDTs (IgG and/or IgM) and 29 (32, 95 %CI: %) were positive according to Borreliose Complete RDT (IgG and/or IgM). Specificity was 88 % (95 %CI: 81 % 94) for Lyme RDTs and 85 % (95 %CI: %) for Borreliose RDT. Of the 118 positive IgM specimens, 23 (19 %) were positive according to both RDTs (Fig. 1). For IgG, 19 out of 118 (16 %) were positive according to both RDTs. The performance of the RDTs was further assessed by dividing the 200 specimens into 18 categories with a gradually increasing probability of Borrelia infection using CLIA, ELISA, Immunoblot test results and clinical symptoms as a combined measure (Table 2). Out of the 28 specimens that were IgG-positive (,, or ) and IgM-negative, only 1 sample (3.6 %) was detected by RDTs. laboratory-based tests in various clinical settings and have become the backbone of national screening policies for sexually transmitted diseases in multiple countries [10]. Although RDTs are a clear success for some diseases, they may not achieve appropriate sensitivities for certain pathogens [11], and as shown in this study, not for the Borrelia burgdorferi sensu stricto either. However, it is essential to know the analytical performance of the tests in order to interpret the possible clinical diagnostic significance of the result. Discussion To the authors knowledge, this is the first study to evaluate the performance of Borrelia RDTs. Currently, RDTs are available for many infectious diseases caused by pathogens like HIVand EBVand have a major public health impact throughout the world [9]. Over the last few years, RDTs have replaced Fig. 1 Venn diagram showing distribution of positive specimens among the three assays. Numbers represent positive specimens detected by three assays (number is given in three overlapping circles), or by two assays (2 overlapping circles) or by one assay (given as number below the assay name). IgG values are represented in black; IgM values are given in purple
4 Table 2 Performance of the Borreliose rapid diagnostic test (RDT) and Lyme RDT. Distribution of reactive specimens (n=146) into 14 categories with increasing probability of Lyme borreliosis infection, using low or high ELISA and CLIA values, immunblot results and clinical symptoms together a Fourteen combinations of IgM and IgG values, aligned with an increasing probability of infection b Category IgG Clinical IgM n (13) (12) Percentage detected by Lyme RDTs Percentage detected by Borreliose Complete RDT negative, low IgM /IgG, high IgM/IgG, immunoblot positive (12) (13) (8) (6) (8) (6) (7) Clinical (21) a IgG was valued over low or high IgM results. A positive immunoblot, regardless of ELISA or CLIA value, was believed to have a high probability of Lyme borreliosis b Left low probability, right high probability Even though the performance of Borreliose Complete RDT was slightly better than that of the Lyme RDTs, the sensitivity in detecting Borrelia IgG or IgM was lower compared with laboratory-based tests. The sensitivity was particularly low for specimens that were IgG-positive and IgM-negative. Even for specimens with high antibody levels, less than 50 % of the positive specimens were detected by RDTs. Additionally, the sensitivity of the RDTs was not associated with our estimated increased probability of infection. It should be noted that serum specimens were used instead of whole blood specimens, limiting translation of the results to a non-laboratory setting. Based on other immunochromatographic test evaluations, performance usually seems to be better with plasma or serum than with whole blood [12], making it more likely that the test results obtained in this study overestimate performance when used with whole blood in a non-laboratory setting. Regardless of the performance of these RDTs, time after infection is essential for valid antibody testing and although speculating, it is very likely that RDTs are used too soon after a tick-bite by the general public to obtain valid results. The analytical specificity of these RDTs was nearly 100 % and did not cross react with treponemal antibodies. Although negative specimens obtained from suspected Lyme disease cases were used in this study, we did not use an extensive, well-characterised panel to assess the specificity in great depth owing to financial restrictions. Because of poor performance the usefulness of these RDTs in a clinical setting is questionable. However, these tests are being purchased by the general public at the local pharmacy for diagnosis at home. Owing to the complexity of Lyme disease diagnosis and the high incidence in Finland, many cases are missed when using RDTs. It is therefore likely that the number of patients seeking appropriate healthcare would be reduced or at least severely delayed because of the availability of these RDTs at the pharmacies. Untreated or very late detection of patients would increase healthcare demand in the long term as infection could lead to arthritis, late dermatological manifestations, myocarditis, meningitis, or neurological damage, such as facial nerve palsy, focal central nervous system damage or neuropathy [1]. Based on this evaluation, the performance of RDTs in detecting Lyme borreliosis appeared to be below that of laboratory-based diagnostics. Acknowledgements We would like to thank Aftab Jasir, Androulla Efstratiou, Triin Pärn and Jaana Vuopio for critically proofreading the manuscript. Conflict of interest interest. References The authors declare that they have no conflict of 1. Stanek G, Wormser GP, Gray J, Strle F (2012) Lyme borreliosis. Lancet 379: Aguero-Rosenfeld M, Wang Q, Schwartz I, Wormser GP (2005) Diagnosis of Lyme borreliosis. Clin Microbiol Rev 18: Jaakola S, Lyytikäinen O, Rimhanen-Finne R et al (2013) Infectious diseases in Finland National Institute of Health and Welfare, Helsinki 4. Busson L, Reynders M, Van den Wijngaert S et al (2012) Evaluation of commercial screening tests and blot assays for the diagnosis of Lyme borreliosis. Diagn Microbiol Infect Dis 73: Lee SH, Vigliotti JS, Vigliotti VS, Jones W, Shearer DM (2014) Detection of borreliae in archived sera from patients with clinically suspect Lyme disease. Int J Mol Sci 15: Ang CW, Notermans DW, Hommes M, Simoons-Smit AM, Herremans T (2011) Large differences between test strategies for the detection of anti-borrelia antibodies are revealed by comparing eight ELISAs and five immunoblots. Eur J Clin Microbiol Infect Dis 30: Smit P, Mabey D, Changalucha J et al (2013) The trade-off between accuracy and accessibility of syphilis screening assays. PLoS One 8: e Mygland A, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I (2010) EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17(8 16):e1 e4
5 9. Mabey D, Peeling RW, Ustianowski A, Perkins MD (2004) Diagnostics for the developing world. Nat Rev Microbiol 2: Mabey DC, Sollis KA, Kelly HA et al (2012) Point-of-care tests to strengthen health systems and save newborn lives: the case of syphilis. PLoS Med 9:e Hurly DS, Buhrer-Skinner M, Badman SG et al (2013) Field evaluation of the CRT and ACON chlamydia point-of-care tests in a tropical, low-resource setting. Sex Transm Infect 90: Herring AJ, Ballard RC, Pope V et al (2006) A multi-centre evaluation of nine rapid, point-of-care syphilis tests using archived sera. Sex Transm Infect 82 [Suppl 5]:v7 v12
LU:research Institutional Repository of Lund University
LU:research Institutional Repository of Lund University This is an author produced version of a paper published in European journal of clinical microbiology & infectious diseases: official publication
More informationLyme Neuroborreliosis
Lyme Neuroborreliosis Presenter: Elitza S. Theel, Ph.D., D(ABMM) Director of Infectious Diseases Serology Co-Director, Vector-Borne Diseases Service Line Department of Laboratory Medicine and Pathology
More informationHumoral Immune Responses in Patients with Lyme Neuroborreliosis
CLINICAL AND VACCINE IMMUNOLOGY, Apr. 2010, p. 645 650 Vol. 17, No. 4 1556-6811/10/$12.00 doi:10.1128/cvi.00341-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Humoral Immune
More informationLyme disease stakeholder scoping workshop
1.1 Who is the focus: Groups that will be covered: Adults and children with a suspected or confirmed diagnosis of Lyme disease 1.2. Settings All setting where NHS care The group suggested that the following
More informationELISA Range. VIROTECH Diagnostics GmbH. Lot independent. Reagent. System. IgG-Conjugate. Substrate. IgM-Conjugate. Washing Solution.
Quelle: www.fotolia.com ELISA Range IgG-Conjugate IgM-Conjugate IgA-Conjugate Lot independent Reagent System Stop Solution Substrate Washing Solution Serum Dilution Dilution Buffer Incubation Time Cerebrospinal
More information1 of 12 23/11/ :25
1 of 12 23/11/2008 09:25 And The Bands Played On - Western blot serological test for Lyme disease http://www.geocities.com/hotsprings/oasis/6455/western-blot.txt ************************************************************************
More informationIntroduction ORIGINAL ARTICLE
Eur J Clin Microbiol Infect Dis (2017) 36:2137 2146 DOI 10.1007/s10096-017-3037-1 ORIGINAL ARTICLE Disagreement between the results from three commercial tests for the detection of Borrelia-specific serum
More informationBlueBLOT-LINE Borrelia. Test Characteristics. Antibody Response
BlueDiver Instrument IMMUNOBLOT KITS FOR DIAGNOSIS OF LYME BORRELIOSIS INFECTIOUS SEROLOGY IN NEW AUTOMATED SYSTEM FOR THE ANALYSIS AND EVALUATION OF IMMUNOBLOTS BlueDiver Instrument, Immunoblot Software
More informationFalse-negative serology in patients with neuroborreliosis and the value of employing of different borrelial strains in serological assays
J. Med. Microbiol. Ð Vol. 49 2000), 911±915 # 2000 The Pathological Society of Great Britain and Ireland ISSN 0022-2615 IMMUNOLOGICAL RESPONSE TO INFECTION False-negative serology in patients with neuroborreliosis
More informationPersistence of Immunoglobulin M or Immunoglobulin G Antibody Responses to Borrelia burgdorferi Years after Active Lyme Disease
MAJOR ARTICLE Persistence of Immunoglobulin M or Immunoglobulin G Antibody Responses to Borrelia burgdorferi 10 20 Years after Active Lyme Disease Robert A. Kalish, 1 Gail McHugh, 1 John Granquist, 1 Barry
More informationPanel # Panel CPT Code Price 2010 AUTOIMMUNE PROFILE - BASIC 99.00
2010 AUTOIMMUNE PROFILE - BASIC 99.00 Anti-Nuclear Antibody (ANA) 86038 33.00 Rheumatoid Factor 86431 33.00 C1Q Immune Complex 86332 33.00 2011 AUTOIMMUNE PROFILE (COMPREHENSIVE) 210.00 Anti-Nuclear Antibody
More informationNOTES. Received 4 November 2005/Returned for modification 30 December 2005/Accepted 2 February 2006
CLINICAL AND VACCINE IMMUNOLOGY, Apr. 2006, p. 525 529 Vol. 13, No. 4 1556-6811/06/$08.00 0 doi:10.1128/cvi.13.4.525 529.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. NOTES
More informationThe chemokine CXCL13 in cerebrospinal fluid in children with Lyme neuroborreliosis
European Journal of Clinical Microbiology & Infectious Diseases (2018) 37:1983 1991 https://doi.org/10.1007/s10096-018-3334-3 ORIGINAL ARTICLE The chemokine CXCL13 in cerebrospinal fluid in children with
More informationLYME DISEASE Last revised May 30, 2012
Wisconsin Department of Health Services Division of Public Health Communicable Disease Surveillance Guideline LYME DISEASE Last revised May 30, 2012 I. IDENTIFICATION A. CLINICAL DESCRIPTION: A multi-systemic
More informationInstructions for Use. Borrelia Veterinary plus OspA LINE
Instructions for Use Borrelia Veterinary plus OspA LINE IgG Line Immunoblot To determine IgG antibodies to Borrelia burgdorferi sensu lato in dog and horse sera Order No.: DE226G32 IgG Line Immunoblot
More informationSerological diagnostics of Lyme borreliosis: comparison of universal and Borrelia. species-specific tests based on whole-cell and recombinant antigens
JCM Accepted Manuscript Posted Online 5 September 2018 J. Clin. Microbiol. doi:10.1128/jcm.00601-18 Copyright 2018 Kodym et al. This is an open-access article distributed under the terms of the Creative
More informationLaboratory Diagnostics:
Laboratory Diagnostics: Utility of Different Test Systems Klaus-Peter Hunfeld, MD, MPH Institute for Laboratory Medicine, Microbiology & Infection Control, Northwest Medical Centre, Frankfurt/Main, Germany
More informationSTATEMENT FOR MANAGING LYME DISEASE IN NOVA SCOTIA
INFECTIOUS DISEASES EXPERT GROUP (IDEG) DEPARTMENT OF HEALTH AND WELLNESS STATEMENT FOR MANAGING LYME DISEASE IN NOVA SCOTIA Executive Summary: In 2016, the Public Health Agency of Canada (PHAC) modified
More informationInfectious Diseases Expert Group (IDEG) Department of Health and Wellness. Statement for Managing Lyme Disease in Nova Scotia
Infectious Diseases Expert Group (IDEG) Department of Health and Wellness Statement for Managing Lyme Disease in Nova Scotia 2018 Executive Summary: In 2016, the Public Health Agency of Canada (PHAC) modified
More informationFatigue, persistence after Lyme borreliosis 196, 197 Francisella tularensis, see Tularemia
Subject Index Acrodermatitis chronica atrophicans (ACA) antibiotic therapy 121, 122 Borrelia induction 13 clinical characteristics 64, 65, 82 diagnosis 65, 66 differential diagnosis 66 etiology 62 frequency
More informationMAJOR ARTICLE. John A. Branda, 1 Katy Linskey, 1 Yeowon A. Kim, 1 Allen C. Steere, 2 and Mary Jane Ferraro 1,2
MAJOR ARTICLE Two-Tiered Antibody Testing for Lyme Disease With Use of 2 Enzyme Immunoassays, a Whole-Cell Sonicate Enzyme Immunoassay Followed by a VlsE C6 Peptide Enzyme Immunoassay John A. Branda, 1
More informationTreponema-Specific Tests for Serodiagnosis of Syphilis: Comparative Evaluation of Seven Assays
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1313 1317 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.02555-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Treponema-Specific
More informationTreponemal-Specific Tests for the Serodiagnosis of Syphilis: A Comparative Evaluation of Seven Assays
JCM Accepts, published online ahead of print on 23 February 2011 J. Clin. Microbiol. doi:10.1128/jcm.02555-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationQ fever. Lyme disease LDA Conference Anja Garritsen 1. Lyme Disease Diagnostics. Today s presentation
Today s presentation Lyme Disease Diagnostics What can we use now What do we need for the future? Anja Garritsen, Innatoss Laboratories, NL Innatoss Diagnostics for Lyme Disease The present Diagnostic
More informationPeter J. Weina, PhD, MD, FACP, FIDSA. Colonel, Medical Corps, US Army Deputy Commander Walter Reed Army Institute of Research
Peter J. Weina, PhD, MD, FACP, FIDSA Colonel, Medical Corps, US Army Deputy Commander Walter Reed Army Institute of Research Background Most common vector-borne disease in U.S. First described in Lyme,
More informationComparative evaluation of three different ELISA methods for the diagnosis of early culture-confirmed Lyme disease in Italy
Journal of Medical Microbiology (2005), 54, 361 367 DOI 10.1099/jmm.0.45853-0 Comparative evaluation of three different ELISA methods for the diagnosis of early culture-confirmed Lyme disease in Italy
More informationDepartment of Medical Microbiology, University Hospital Maastricht, Maastricht, The Netherlands
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01448.x Comparison of five different immunoassays for the detection of Borrelia burgdorferi IgM and IgG antibodies A. Smismans, V. J. Goossens, E. Nulens and C.
More informationChanges in antibody reactivity to Borrelia burgdorferi three months after a tick bite. A cohort of 1,886 persons
CVI Accepted Manuscript Posted Online 20 May 2015 Clin. Vaccine Immunol. doi:10.1128/cvi.00026-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13 14
More informationHigh sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients
ORIGINAL ARTICLE BACTERIOLOGY High sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients N. D. van Burgel 1, A. Brandenburg 2, H. J. Gerritsen 1,
More informationTechnical Bulletin No. 121
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 121 January 31, 2014 Lyme Blot, IgG and IgM - Now Performed at CPAL Contact: J. Matthew Groeller, 717.851.1416 Operations Manager, Clinical
More informationLyme Disease Surveillance in Wisconsin Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/2014
Lyme Disease Surveillance in Wisconsin Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/2014 Protecting and promoting the health and safety of the people of Wisconsin
More informationLyme Disease. Abstract Lyme disease is a vector borne infection primarily transmitted by Ixodes ticks and. Special Issue
Special Issue Lyme Disease Min Geol Lee, M.DYoung Hun Cho, M.D. Department of Dermatology Yonsei University College of Medicine, Severance Hospital Email : mglee@yumc.yonsei.ac.krsalute@yumc.yonsei.ac.kr
More informationKesia Backman 1 and Barbro H. Skogman 2,3*
Backman and Skogman BMC Pediatrics (2018) 18:189 https://doi.org/10.1186/s12887-018-1163-2 RESEARCH ARTICLE Occurrence of erythema migrans in children with Lyme neuroborreliosis and the association with
More informationReceived 7 March 2002/Returned for modification 21 June 2002/Accepted 10 July 2002
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2002, p. 1348 1355 Vol. 9, No. 6 1071-412X/02/$04.00 0 DOI: 10.1128/CDLI.9.6.1348 1355.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationLyme disease conference
Lyme disease conference Epidemiology of Lyme in England and Wales Robert Smith, Public Health Wales 9 October 213 Lyme disease in England and Wales Dr Robert Smith Health Protection Division Public Health
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Intravenous Antibiotic Therapy and Associated Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Intravenous Antibiotic Therapy and Associated Professional
More informationAnimal Health Diagnostic Center. Lyme Disease Multiplex Testing for Dogs. Background on Lyme disease and Lyme diagnostics in dogs
Animal Health Diagnostic Center Lyme Disease Multiplex Testing for Dogs Background on Lyme disease and Lyme diagnostics in dogs Lyme disease is induced by the spirochete B. burgdorferi. Spirochetes are
More informationAnalytical Comparison of the Architect Syphilis TP and Liaison Treponema Assay
JCM Accepted Manuscript Posted Online 16 May 2018 J. Clin. Microbiol. doi:10.1128/jcm.00215-18 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 3 Analytical Comparison of the
More informationInfectious Diseases (S.K. Morris), and Division of Microbiology (S.E.Richardson),
JCM Accepts, published online ahead of print on 10 November 2010 J. Clin. Microbiol. doi:10.1128/jcm.01584-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationBorrelia burgdorferi sensu lato complex Assay
Borrelia burgdorferi sensu lato complex Assay For the detection of Borrelia burgdorferi sensu lato complex (ospa- and p41(flagellin) genes) using the BD MAX TM system. Instructions for use (Version 1.0
More informationTreponema Pallidum (TP) Antibody Test
Treponema Pallidum (TP) Antibody Test Instructions For Use Format: Cassette For: Catalog Number: VEL-001-TP Specimen: Serum/Plasma * Please read the instructions carefully before use INTENDED USE Velotest
More informationIdentifying false-positive syphilis antibody results using a semi-quantitative
CVI Accepts, published online ahead of print on 20 April 2011 Clin. Vaccine Immunol. doi:10.1128/cvi.05066-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationThere is no Lyme Disease in Ireland?
Dear Sirs, Registered Charity: 19588 "Encouraging awareness, prevention & treatment of Lyme Disease (Borreliosis) in Ireland." There is no Lyme Disease in Ireland? I am writing to you with sincere concerns
More informationDesign Verification. Form:
Design Verification SYPHILIS TPHA liquid CONTENTS 1 Function... 2 2 Sensitivity... 2 Preparation of Serum Control Panel... 2 Kit Controls Positive and Negative... 3 3 Traceability... 3 4 Specificity and
More information4/18/2018. Syphilis Testing. Disclosure. Learner Objectives. Outline. Employee and stockholder of Bio-Rad Laboratories, Inc.
Disclosure Employee and stockholder of Bio-Rad Laboratories, Inc. Unraveling the Complexities of Syphilis Testing Maria Crisostomo, April 30 & May 1, 2018 2 Learner Objectives Syphilis Testing Upon completion
More informationIntravenous Antibiotic Therapy and Associated Diagnostic Testing for Lyme Disease
Intravenous Antibiotic Therapy and Associated Diagnostic Testing for Lyme Disease Policy Number: 5.01.08 Last Review: 01/2018 Origination: 1/2009 Next Review: 01/2019 Policy Blue Cross and Blue Shield
More informationTreponema pallidum Total ELISA Kit
Treponema pallidum Total ELISA Kit Catalog Number KA0970 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationSerological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections?
Abstract no. WEPE 494 Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections? G.Chrysos 1, D.Karageorgopoulos
More informationtest. It appeared that the MHA-TP test could be
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1983, p. 405-409 0095-1137/83/030405-05$02.00/0 Copyright 1983, American Society for Microbiology Vol. 17, No. 3 Reactivity of Microhemagglutination, Fluorescent
More informationWestern Blot Analysis for Diagnosis of Lyme Disease in Acute Facial Palsy
The Laryngoscope Lippincott Williams & Wilkins, Inc., Philadelphia 2001 The American Laryngological, Rhinological and Otological Society, Inc. Western Blot Analysis for Diagnosis of Lyme Disease in Acute
More informationMP Intravenous Antibiotic Therapy and Associated Diagnostic Testing for Lyme Disease. Related Policies None
Medical Policy BCBSA Ref. Policy: 5.01.08 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Prescription Drug Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationGeneral practitioner reported incidence of Lyme carditis in the Netherlands
Neth Heart J (2015) 23:533 538 DOI 10.1007/s12471-015-0744-z Original Article General practitioner reported incidence of Lyme carditis in the Netherlands A. Hofhuis S.M. Arend C.J. Davids R. Tukkie W.
More informationBorrelia B31 ViraChip IgG Test Kit
Borrelia B31 ViraChip IgG Test Kit Intended Use: The Viramed Biotech AG Borrelia B31 ViraChip IgG Test Kit is an in vitro qualitative protein microarray assay for the detection of IgG antibodies to Borrelia
More informationAnti-Borrelia burgdorferi Antibody Profile in Post-Lyme Disease Syndrome
CLINICAL AND VACCINE IMMUNOLOGY, May 2011, p. 767 771 Vol. 18, No. 5 1556-6811/11/$12.00 doi:10.1128/cvi.00002-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Anti-Borrelia burgdorferi
More informationTreponema Pallidum Total Antibody ELISA
For Research Use Only. Not for use in Diagnostic Procedures. INTENDED USE The GenWay, Inc. Treponima pallidum Total ELISA Kit is intended for the detection of IgG, IgM and IgA antibody to Treponima pallidum
More informationTreponema pallidum IgM ELISA Kit
Treponema pallidum IgM ELISA Kit Catalog Number KA0969 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationA study of point-of-care test to diagnose syphilis in Hong Kong
Hong Kong J. Dermatol. Venereol. (2015) 23, 5-12 Original Article A study of point-of-care test to diagnose syphilis in Hong Kong CC Koh, CK Ho, KM Ho Background: In Hong Kong, a 'point-of-care' test (POC)
More informationBorrelia afzelii + VlsE IgG ELISA IgG Test Kit
Borrelia afzelii + VlsE IgG ELISA IgG Test Kit Including performance data for CSF diagnosis Order-No.: EC022G00 (IgG Testkit) Order-No.: EC022L60 (IgG CSF-Standards) Colour coding: gold/red FOR IN VITRO
More informationEvaluation of the LIAISON Treponema Assay, a Chemiluminescent Immunoassay ACCEPTED
CVI Accepts, published online ahead of print on 25 April 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00068-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationReceived 22 November 2004/Returned for modification 14 January 2005/Accepted 17 April 2005
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2005, p. 3602 3609 Vol. 43, No. 8 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.8.3602 3609.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationThe views expressed in this publication do not necessarily reflect the views of the European Centre for Disease Prevention and Control (ECDC).
Background Summary of work activities Pieter W. Smit European Public Health Microbiology Training Programme (EUPHEM), 2012 cohort According to the European Centre for Disease Prevention and Control (ECDC)
More informationSYPHILIS HEALTH CHECK
SYPHILIS HEALTH CHECK Rev. P, 02/17 CLIA Complexity: WAIVED for Fingerstick Whole Blood Specimens ONLY For in vitro diagnostic use only Rx Only A Certificate of Waiver is required to perform this test
More informationDiagnostic and Biological Significance of Anti-p41 IgM Antibodies against Borrelia burgdorferi
Scand. J. Immunol. 53, 416±421, 2001 Diagnostic and Biological Significance of Anti-p41 IgM Antibodies against Borrelia burgdorferi E. ULVESTAD,* A. KANESTRéM,* L. J. SéNSTEBY,* R. JUREEN,* T. OMLAND,*
More informationSerodiagnosis of Lyme Borreliosis by Borrelia burgdorferi Sensu Stricto, B. garinii, and B. afzelii Western Blots (Immunoblots)
JOURNAL OF CLINICAL MICROBIOLOGY, July 1996, p. 1732 1738 Vol. 34, No. 7 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Serodiagnosis of Lyme Borreliosis by Borrelia burgdorferi
More informationPRICE LIST Effective Date: October 16, 2017
Effective October 16, 2017 we are offering our new tests for Lyme IGXSpot, Lyme Borreliosis, and Tick-borne Relapsing Fever Borreliosis The new ImmunoBlot tests have replaced the original Western Blot
More informationTitle: Revisiting the Lyme Disease Serodiagnostic Algorithm: The Momentum Gathers
JCM Accepted Manuscript Posted Online 13 June 2018 J. Clin. Microbiol. doi:10.1128/jcm.00749-18 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 Title: Revisiting the Lyme Disease
More informationUpdate on Lyme Disease Surveillance in Wisconsin for Providers and Laboratories
Update on Lyme Disease Surveillance in Wisconsin for Providers and Laboratories Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/14 Protecting and promoting the
More informationCorporate Medical Policy
Corporate Medical Policy Intravenous Antibiotic Therapy for Lyme Disease File Name: intravenous_antibiotic_therapy_for_lyme_disease Origination: 3/2006 Last CAP Review: 2/2017 Next CAP Review: 2/2018 Last
More informationPE1662/E Lyme Disease Action submission of 27 October 2017
PE1662/E Lyme Disease Action submission of 27 October 2017 We support the petitioners calls for action to improve the position with regard to awareness, diagnosis and treatment of Lyme disease. We would
More informationSUPPLEMENTARY INFORMATION. Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease
SUPPLEMENTARY INFORMATION Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease Samiksha Nayak 1, Archana Sridhara 1, Rita Melo 2, Luciana Richer 3, Natalie H. Chee 1, Jiyoon Kim 1,
More informationInterpretation Criteria for Standardized Western Blots for Three European Species of Borrelia burgdorferi Sensu Lato
JOURNAL OF CLINICAL MICROBIOLOGY, June 1997, p. 1433 1444 Vol. 35, No. 6 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Interpretation Criteria for Standardized Western Blots for
More informationNon-commercial use only
Microbiologia Medica 2017; volume 32:6583 Evaluation of the TGS TA system for the detection of anti-toxoplasma antibodies Olivia Arpino, Annalisa Cianflone, Maria Teresa Manco, Alessia Paganini, Massimo
More informationReceived 30 August 2010/Returned for modification 27 September 2010/Accepted 12 November 2010
CLINICAL AND VACCINE IMMUNOLOGY, Jan. 2011, p. 167 172 Vol. 18, No. 1 1556-6811/11/$12.00 doi:10.1128/cvi.00367-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Acute Parvovirus
More informationMR imaging findings in neuro-lyme disease.
MR imaging findings in neuro-lyme disease. Poster No.: C-0594 Congress: ECR 2017 Type: Educational Exhibit Authors: M. D. M. Cordon Holzknecht 1, E. Salvado 1, A. Samitier Pastor 1, L. E. Guerrero 2, O.
More informationAn outer surface protein C (OspC) peptide derived from Borrelia burgdorferi sensu. strico as a target for the serodiagnosis of early Lyme disease.
CVI Accepts, published online ahead of print on 30 January 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00608-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 An outer
More informationBorrelia afzelii IgM ELISA IgM Test Kit
Borrelia afzelii IgM ELISA IgM Test Kit Including performance data for CSF diagnosis Order no: EC022M00 (IgM Test Kit) Order-No.: EC022L80 (IgM CSF-Standards) Colour coding: gold/pale blue FOR IN VITRO
More informationb Ospea ale Ciuile di Gemona, Gemona, Italy
ELSEVIER FEMS Immunology and Medical Microbiology 14 (1996) 159-166 /f~d~blf~ogy MICROBIOLOGY AND Abstract IgM and IgG significant reactivity to Borrelia burgdorferi sense stricto, Borrelia garinii and
More informationGenotypic characterization and historical perspective of Mycobacterium tuberculosis among older and younger Finns,
ORIGINAL ARTICLE BACTERIOLOGY Genotypic characterization and historical perspective of Mycobacterium tuberculosis among older and younger Finns, 2008 2011 P. W. Smit 1,2, M. Haanper a 2, P. Rantala 2,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21004 holds various files of this Leiden University dissertation. Author: Burgel, Nathalie Daniëlle van Title: Host-pathogen interactions in Lyme disease
More informationCase report: persistently seronegative neuroborreliosis in an immunocompromised patient
Wagemakers et al. BMC Infectious Diseases (2018) 18:362 https://doi.org/10.1186/s12879-018-3273-8 CASE REPORT Open Access Case report: persistently seronegative neuroborreliosis in an immunocompromised
More informationPanel & Test Price List Effective Date: October 16, 2017
-New tests now available: Bartonella IGXSpot, Bartonella Western Blot IgG & IgM -Tests Now available for New York residents: Lyme ImmunoBlots IgG & IgM *IGXSP IGXSpot Panel $442.50 Lyme IGXSpot 86352 Bartonella
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21004 holds various files of this Leiden University dissertation. Author: Burgel, Nathalie Daniëlle van Title: Host-pathogen interactions in Lyme disease
More informationUtility of Borrelia burgdorferi sensu stricto C6 Peptide for Serologic Confirmation of Erythema-free Ixodid Tick-borne Borrelioses in Russia
Utility of Borrelia burgdorferi sensu stricto C6 Peptide for Serologic Confirmation of Erythema-free Ixodid Tick-borne Borrelioses in Russia Vera Pomelova 1*, Edward Korenberg 2, Tatyana Kuznetsova 3,
More informationResearch Article Evaluating Frequency, Diagnostic Quality, and Cost of Lyme Borreliosis Testing in Germany: A Retrospective Model Analysis
Hindawi Publishing Corporation Clinical and Developmental Immunology Volume 2012, Article ID 595427, 13 pages doi:10.1155/2012/595427 Research Article Evaluating Frequency, Diagnostic Quality, and Cost
More informationA European Multicenter Study of Immunoblotting in Serodiagnosis of Lyme Borreliosis
JOURNAL OF CLINICAL MICROBIOLOGY, June 2000, p. 2097 2102 Vol. 38, No. 6 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. A European Multicenter Study of Immunoblotting
More informationLinköping University Post Print. Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-
Linköping University Post Print Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6- peptide in Lyme neuroborreliosis. Ivar Tjernberg, Anna J Henningsson, Ingvar Eliasson,
More informationUse of Treponemal Immunoassays for Screening and Diagnosis of Syphilis
Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis Guidance for Medical Providers and Laboratories in California These guidelines were developed by the California Department of Public
More informationClinical Application of New Treponemal Antibody Test in Blood Donors
Clinical Application of New Treponemal Antibody Test in Blood Donors Parichart Permpikul, MD Department of Transfusion Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok, Thailand
More informationReceived 23 November 1998/Returned for modification 8 March 1999/Accepted 6 April 1999
JOURNAL OF CLINICAL MICROBIOLOGY, July 1999, p. 2241 2247 Vol. 37, No. 7 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Validity of Interpretation Criteria
More informationDirect Comparison of the Traditional and Reverse Syphilis Screening Algorithms
JCM Accepts, published online ahead of print on 16 November 2011 J. Clin. Microbiol. doi:10.1128/jcm.05636-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationComparison of Different Strains of Borrelia burgdorferi Sensu Lato Used as Antigens in Enzyme-Linked Immunosorbent Assays
JOURNAL OF CLINICAL MICROBIOLOGY, May 1994, p. 1154-1158 Vol. 32, No. 5 0095-1 137/94/$04.00+0 Copyright C) 1994, American Society for Microbiology Comparison of Different Strains of Borrelia burgdorferi
More informationChlamydia trachomatis (CHLa)Test Kit
Chlamydia trachomatis (CHLa)Test Kit Instructions For Use Format: Cassette Specimen: Urethral/Genital Swab Catalog Number: VEL-001-CHLa * Please read the instructions carefully before use INTENDED USE
More informationPublic Statement: Medical Policy Statement:
Medical Policy Title: Lyme Disease, Intravenous Antibiotic Therapy ARBenefits Approval: 10/19/2011 and Associated Diagnostic Testing Effective Date: 01/01/2012 Document: ARB0235 Revision Date: Code(s):
More informationMycoplasma pneumoniae IgG ELISA Kit
Mycoplasma pneumoniae IgG ELISA Kit Catalog Number KA2260 96 assays Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationNovel Point-of-Care Test for Simultaneous Detection of Nontreponemal and Treponemal Antibodies in Patients with Syphilis
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2010, p. 4615 4619 Vol. 48, No. 12 0095-1137/10/$12.00 doi:10.1128/jcm.00624-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Novel Point-of-Care
More information